Stars 0 No Patient
Satisfaction Reviews
Why not?
SHOW ALL RATINGS+
Specialty:

Pathology
Anatomic and Clinical Pathology

Board Certifications:

  • Pediatric Pathology
  • Anatomic Pathology

Education:

MD, National Autonomous University of Mexico Mexico City, Mexico

Residency:

Hospital General de Mexico
Mexico City, Mexico
Childrens Memorial Hospital
Chicago, IL
Yale New Haven Hospital
New Haven, CT

Affiliations:

Magee-Womens Hospital of UPMC
Children's Hospital of Pittsburgh of UPMC

Languages:

Spanish
Portuguese

Miguel Reyes-Mugica, MD

Doctor

Chief of Pathology and Director of Laboratories, Children's Hospital of Pittsburgh of UPMC

Locations and Directions

SHOW ALL LOCATIONS+

Biography

Research Interests

Dr. Miguel Reyes-Múgica has been involved in studies of childhood tumors and defects of neural crest cell migration. In the first group, he has studied neuroblastoma, a neural crest derived neoplasm with heterogeneous biology and clinical behavior, in which the therapeutic advances have developed with difficulty. He also studies another neural crest disorder called neurocutaneous melanosis. Patients with this condition are born with large pigmented nevi (moles) and later develop meningeal/brain melanocytic proliferations. As a member of the Scientific Advisory Board of Nevus Outreach, Inc., a consultation service for conditions related to Giant Melanocytic Nevi and Neurocutaneous Melanosis is offered. A third condition within his interest is Hirschsprung disease (congenital megacolon), in which neural crest-derived ganglion cells are not present in the colonic nervous system, leading to chronic constipation. Studies to improve our diagnostic ability are being conducted.

In addition, the pathology of pediatric testicular lesions has become an important focus of Dr. Reyes-Mugica’s Research Interest. He has published extensively on issues of Pediatric Testicular Pathology, and participates in a monthly clinic at CHP studying patients with Disorders of Sex Development. His contributions to Perspectives in Pediatric Pathology have appeared as part of a supplement for the Journal Pediatric and Developmental Pathology, and will appear as a bound volume containing 25 chapters dedicated to this topic, at the end of 2016.

  • Biological Studies on Neurocutaneous Melanosis and Giant Pigmented Nevi
  • ELGAN study

View Dr. Reyes-Múgica's full list of publications from PubMed.

Biography Summary

Dr. Miguel Reyes-Múgica, born and educated in México began his career in the USA in 1990. He graduated from the School of Medicine, National University of Mexico (UNAM) in 1982. He trained in Anatomic Pathology under Dr. Ruy Pérez Tamayo, a world recognized pathologist, scientist and medical writer. Before migrating to the USA, Dr. Reyes was Attending Pathologist at the National Institute of Pediatrics (INP), in México City. In 1990, Dr. Reyes began working under the mentorship of Dr. González-Crussí, a world-leading pediatric pathologist at Children’s Memorial Hospital (CMH), Northwestern University, in Chicago. In 1994, Dr. Reyes accepted a position at the Department of Pathology at Yale, where he established the Program of Pediatric and Developmental Pathology, and remained as Director of such program for 14 years. During that period, he escalated the academic ladder and he was appointed Professor of Pathology and Pediatrics at the Yale University School of Medicine. In July of 2008, he accepted the position of Chief of Pathology at the Children’s Hospital of Pittsburgh of UPMC, and Chief of the Division of Pediatric Pathology, at the Department of Pathology, UPMC. Since 2001, Dr. Reyes-Múgica is Editor-in-Chief of the Journal Pediatric and Developmental Pathology, the leading journal in the field, and the official voice of the Society for Pediatric Pathology, and the Paediatric Pathology Society.

Dr. Reyes’ research activities are wide and cover a large extent of the general field of Pediatric Pathology. He has concentrated his efforts in the area of pediatric neoplasia and developmental disorders, studying brain tumors and neural crest disorders, such as neuroblastoma, Hirschsprung disease, and neurocutaneous melanocytosis (NCM). He explored neoplastic development and migration studying the role of the gene DCC in the ability of gliomas and neuroblastoma cells to migrate, disseminate and metastasize, and found a correlation between loss of DCC and increased metastatic potential of these lethal tumors. He also studied the interaction between DCC and N-cadherin in neuroblastoma cells, providing original evidence towards the understanding of the physiological role of DCC. He has studied other features of neuroblastoma, exploring correlations between regulation of apoptosis and clinical behavior. In the same field of neurocristopathies, Dr. Reyes has studied the pathology, biology and genetics of nevomelanocytic lesions in children, specifically concentrating on NCM and giant pigmented nevi (GPN). He has described a previously unrecognized form of GPN: Bulky Perineal Nevocytoma; he also studied the spectrum of lesions involving patients with Touraine syndrome or NCM. His efforts have been sponsored and funded by the organization Nevus Outreach, Inc. (NOI), formed by patients and families with children afflicted by GPN and NCM. In the same field of neoplasia, Dr. Reyes has conducted studies on cancer predisposition syndromes, including Beckwith-Wiedemann, Frasier, Gorlin, Bloom and Sipple syndromes, among others. A more recent field of research is developmental testicular pathology. Dr. Reyes-Múgica’s expertise in Pediatric Testicular Pathology, documented by numerous publications on the topic, has made him a reference for consultations in this field. He is a frequent speaker at national and international meetings, and serves as Information and Technology Director for the Advanced Course of the International Paediatric Pathology Association (IPPA).

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and are displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

Total Comments: 0

SHOW ALL COMMENTS+